I have asked the CEO Prof Iltescu about bone degeneration at the AGM in a direct chat. Right now the stage 3 clinical trials are for disc degeneration, between vertabrae, but they have a big pipeline of applications and you can expect to hear developments in the future.
It seems their strategy is to get the easiest and most lucrative products to market the first. Others will follow.
MSB is providing non autologous stem cells, which means the treatments can be scaled up and offered on a wider basis, and less expensively than autologous treatments.
Open at $2.25, page-46
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.055(5.24%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.13 | $1.04 | $6.781M | 6.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 43856 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 66000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |